
Phillip Decker
Examiner (ID: 475, Phone: (571)270-3088 , Office: P/3749 )
| Most Active Art Unit | 3749 |
| Art Unit(s) | 3743, 3749, 3762 |
| Total Applications | 586 |
| Issued Applications | 321 |
| Pending Applications | 9 |
| Abandoned Applications | 261 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20676441
[patent_doc_number] => 20260115250
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-04-30
[patent_title] => METHODS OF TREATING AGE-RELATED MACULAR DEGENERATION
[patent_app_type] => utility
[patent_app_number] => 19/433697
[patent_app_country] => US
[patent_app_date] => 2025-12-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17884
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19433697
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/433697 | METHODS OF TREATING AGE-RELATED MACULAR DEGENERATION | Dec 25, 2025 | Pending |
Array
(
[id] => 20749275
[patent_doc_number] => 20260151493
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-06-04
[patent_title] => TRI-AGONISTS OF THE GLP-1, GIP, AND AMYLIN RECEPTORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 19/404431
[patent_app_country] => US
[patent_app_date] => 2025-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39166
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19404431
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/404431 | TRI-AGONISTS OF THE GLP-1, GIP, AND AMYLIN RECEPTORS AND USES THEREOF | Nov 30, 2025 | Pending |
Array
(
[id] => 20497719
[patent_doc_number] => 20260027176
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-01-29
[patent_title] => LEUPROLIDE ACETATE COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT BREAST CANCER
[patent_app_type] => utility
[patent_app_number] => 19/345133
[patent_app_country] => US
[patent_app_date] => 2025-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13567
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19345133
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/345133 | LEUPROLIDE ACETATE COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT BREAST CANCER | Sep 29, 2025 | Pending |
Array
(
[id] => 20459389
[patent_doc_number] => 20260008812
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-01-08
[patent_title] => CELL-PENETRATING PEPTIDE COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 19/329410
[patent_app_country] => US
[patent_app_date] => 2025-09-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24320
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19329410
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/329410 | CELL-PENETRATING PEPTIDE COMPOUNDS | Sep 14, 2025 | Pending |
Array
(
[id] => 20534474
[patent_doc_number] => 12551525
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-02-17
[patent_title] => Collagen peptide-based medicament compositions and devices and methods of production and use thereof
[patent_app_type] => utility
[patent_app_number] => 19/085432
[patent_app_country] => US
[patent_app_date] => 2025-03-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 13936
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 168
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19085432
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/085432 | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | Mar 19, 2025 | Issued |
Array
(
[id] => 20098983
[patent_doc_number] => 20250228919
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-17
[patent_title] => Insulin Derivative
[patent_app_type] => utility
[patent_app_number] => 19/052262
[patent_app_country] => US
[patent_app_date] => 2025-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27905
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19052262
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/052262 | Insulin Derivative | Feb 11, 2025 | Abandoned |
Array
(
[id] => 19691297
[patent_doc_number] => 20250009842
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-09
[patent_title] => Methods for Regulating Muscle Performance using Fat Specific Protein 27 (FSP27) Compositions
[patent_app_type] => utility
[patent_app_number] => 18/802702
[patent_app_country] => US
[patent_app_date] => 2024-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13568
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18802702
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/802702 | Methods for Regulating Muscle Performance using Fat Specific Protein 27 (FSP27) Compositions | Aug 12, 2024 | Pending |
Array
(
[id] => 19570396
[patent_doc_number] => 20240374688
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-14
[patent_title] => Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia
[patent_app_type] => utility
[patent_app_number] => 18/785340
[patent_app_country] => US
[patent_app_date] => 2024-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15461
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18785340
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/785340 | Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia | Jul 25, 2024 | Pending |
Array
(
[id] => 19798973
[patent_doc_number] => 20250064898
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-27
[patent_title] => INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION
[patent_app_type] => utility
[patent_app_number] => 18/769016
[patent_app_country] => US
[patent_app_date] => 2024-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15939
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 83
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18769016
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/769016 | INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION | Jul 9, 2024 | Pending |
Array
(
[id] => 19830944
[patent_doc_number] => 20250082730
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-13
[patent_title] => TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA WITH EXENDIN (9-39)
[patent_app_type] => utility
[patent_app_number] => 18/745091
[patent_app_country] => US
[patent_app_date] => 2024-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17170
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18745091
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/745091 | TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA WITH EXENDIN (9-39) | Jun 16, 2024 | Pending |
Array
(
[id] => 19762190
[patent_doc_number] => 12220461
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-11
[patent_title] => Polypeptide-coupled small molecule compound and antiviral application thereof
[patent_app_type] => utility
[patent_app_number] => 18/667958
[patent_app_country] => US
[patent_app_date] => 2024-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 21
[patent_no_of_words] => 6653
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18667958
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/667958 | Polypeptide-coupled small molecule compound and antiviral application thereof | May 16, 2024 | Issued |
Array
(
[id] => 19387947
[patent_doc_number] => 20240277817
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-22
[patent_title] => SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID
[patent_app_type] => utility
[patent_app_number] => 18/643038
[patent_app_country] => US
[patent_app_date] => 2024-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8823
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18643038
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/643038 | SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | Apr 22, 2024 | Pending |
Array
(
[id] => 19554929
[patent_doc_number] => 20240366721
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => Methods and Compositions for Treatment of Angiogenic Disorders Using Anti-VEGF Agents
[patent_app_type] => utility
[patent_app_number] => 18/640840
[patent_app_country] => US
[patent_app_date] => 2024-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10012
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18640840
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/640840 | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents | Apr 18, 2024 | Issued |
Array
(
[id] => 19768257
[patent_doc_number] => 20250049683
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-13
[patent_title] => COMPOSITIONS AND METHODS FOR INHIBITING HAIR GROWTH
[patent_app_type] => utility
[patent_app_number] => 18/591891
[patent_app_country] => US
[patent_app_date] => 2024-02-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12832
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18591891
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/591891 | COMPOSITIONS AND METHODS FOR INHIBITING HAIR GROWTH | Feb 28, 2024 | Abandoned |
Array
(
[id] => 19526675
[patent_doc_number] => 20240350577
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-24
[patent_title] => METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY
[patent_app_type] => utility
[patent_app_number] => 18/588617
[patent_app_country] => US
[patent_app_date] => 2024-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19598
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18588617
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/588617 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY | Feb 26, 2024 | Abandoned |
Array
(
[id] => 19379356
[patent_doc_number] => 20240269226
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-15
[patent_title] => COMBINATION THERAPY WITH SEMAX AND CANNABIDIOL
[patent_app_type] => utility
[patent_app_number] => 18/434973
[patent_app_country] => US
[patent_app_date] => 2024-02-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6110
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18434973
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/434973 | COMBINATION THERAPY WITH SEMAX AND CANNABIDIOL | Feb 6, 2024 | Pending |
Array
(
[id] => 19403627
[patent_doc_number] => 20240287138
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 18/429587
[patent_app_country] => US
[patent_app_date] => 2024-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 65809
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 1421
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18429587
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/429587 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | Jan 31, 2024 | Pending |
Array
(
[id] => 19359335
[patent_doc_number] => 20240261369
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => METHODS FOR REGULATING FREE FATTY ACID FLUX USING FAT SPECIFIC PROTEIN 27 (FSP27) COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/422307
[patent_app_country] => US
[patent_app_date] => 2024-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8409
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18422307
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/422307 | METHODS FOR REGULATING FREE FATTY ACID FLUX USING FAT SPECIFIC PROTEIN 27 (FSP27) COMPOSITIONS | Jan 24, 2024 | Pending |
Array
(
[id] => 19319589
[patent_doc_number] => 20240241132
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-18
[patent_title] => Atomic Description of Immune Complex that Causes Heparin-Induced Thrombocytopenia
[patent_app_type] => utility
[patent_app_number] => 18/420177
[patent_app_country] => US
[patent_app_date] => 2024-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18306
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18420177
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/420177 | Atomic description of immune complex that causes heparin-induced thrombocytopenia | Jan 22, 2024 | Issued |
Array
(
[id] => 19510492
[patent_doc_number] => 20240342178
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-17
[patent_title] => COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 18/414690
[patent_app_country] => US
[patent_app_date] => 2024-01-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11402
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18414690
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/414690 | Combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | Jan 16, 2024 | Issued |